Assessing the clinical impacts of immunomodulatory withdrawal from anti-tnf combination therapy in pediatric inflammtory bowel disease

Combination therapy consists of both a monoclonal antibody against tumor necrosis factor (anti-TNF) (infliximab (IFX) or adalimumab (ADA)) and an immunomodulator (IMM) (thiopurines (TP) or methotrexate (MTX)). Although combination therapy improves clinical outcomes, the IMM may be discontinued to mitigate the risk of IMM-related adverse events. However, it is unknown how de-escalation impacts clinical outcomes in children with IBD.
Source: Gastroenterology - Category: Gastroenterology Authors: Source Type: research